- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06371911
Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment (OPTIMACURE)
Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment: a Multicentric French Prospective Randomized Study: The OPTIMACURE Protocol
Currently, during usual care, it is critical to assess whether a patient is apt to receive injectable anticancer treatment in the days prior to the administration. To assess this, blood tests are usually performed in the days leading up to the planned administration. A hospital staff member then telephones the patients and evaluates, using the tests results and other patient data (including the presence of adverse events (AEs) and Eastern Cooperative Oncology Group [ECOG] performance status), whether the patient is apt for treatment or whether the treatment needs to be deferred.
In France, the Centre François Baclesse in Caen (France) launched the OPTIMA program to optimize the prescription and preparation of chemotherapy in the ambulatory unit of the hospital.
A prospective study validating the OPTIMA program found that the prescription of chemotherapy was accurate with significantly reduced waiting times for patients between the planned appointment time and initiation of chemotherapyThe OPTIMA program is now part of usual care at the Centre François Baclesse.
Following the positive impact of both the OPTIMA and "Star" programs, several French healthcare centers have implemented similar programs. However, a large proportion of the data during the program are collected by telephone, particularly outgoing calls (from the hospital staff to patients). Thus, implementing these programs is expected to increase the number and/or duration of outgoing calls and consequently the workload of hospital staff.
Since the deployment of the OPTIMA program (between 2014 and 2016), and other equivalent programs, more and more patients have asked for the telephone calls to be replaced by a web-based application. Indeed, patients do not always respond to the telephone calls made by hospital staff, thus forcing staff to repeat calls several times. Also, some patients with language or hearing difficulties are unable to answer the questionnaires by telephone: a web-based alternative would be more appropriate for these patients.
Telemonitoring can collect blood test results and other patient data required to evaluate whether patients are apt for injectable cancer treatment. Telemonitoring can then identify the few patients that need to be contacted by hospital staff, thus reducing the number of outgoing telephone calls.
There is growing evidence of the benefits of adding telemonitoring to usual care for patients undergoing cancer treatment. The benefits include the early detection of AEs, improved quality of life (QoL), fewer admissions to emergency rooms or hospitalization, the longer remaining on chemotherapy for patients, and extended overall survival.
Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool includes questionnaires for each class of medication to monitor patients' adverse events remotely. The data collected include blood results, treatment-related data (including delays, dose reductions), as well as QoL and safety data. In terms of safety, patients respond to an electronic patient-reported outcome (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0. Depending on the responses, the Cureety TechCare algorithm classifies the patient state as "correct", "compromised", "to be monitored", or "critical". The patients are then notified of the actions to be taken according to their classification. In preparation for injectable cancer treatment, Cureety can collect the data necessary to evaluate whether patients are apt for treatment administration. The collection and evaluation of this data is expected to decrease outgoing calls by between 30% to 50%.
This study was designed to evaluate whether adding Cureety telemonitoring to usual care would reduce the number of outgoing calls for hospital staff during the management of patients undergoing injectable at one of the participating centers compared with the usual care including a program for anticipation of injectable treatment (OPTIMA program or equivalent).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-Michel GRELLARD
- Phone Number: +33 2 31 45 50 50
- Email: jm.grellard@baclesse.unicancer.fr
Study Contact Backup
- Name: Audrey FAVEYRIAL, MD
- Phone Number: +33 2 31 45 50 50
- Email: a.faveyrial@baclesse.unicancer.fr
Study Locations
-
-
-
Bligny, France
- Not yet recruiting
- Centre Hospitalier de Bligny
-
Contact:
- Jean-Baptiste MERRIC, MD
- Email: jb.meric@chbligny.fr
-
Principal Investigator:
- Jean-Baptiste MERRIC, MD
-
Caen, France, 14000
- Recruiting
- Centre François Baclesse
-
Contact:
- Jean-Michel GRELLARD
- Email: jm.grellard@baclesse.unicancer.fr
-
Contact:
- Audrey Faveyrial, MD
- Email: a.faveyrial@baclesse.unicancer.fr
-
Principal Investigator:
- Audrey Faveyrial, MD
-
Osny, France
- Not yet recruiting
- Centre de Radiothérapie et Oncologie Médicale d'Osny
-
Contact:
- Abderrezak LADOUANI, MD
- Email: a.ladouani@crom95.com
-
Principal Investigator:
- Abderrezak LADOUANI, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria
- Patients that have provided written informed consent for study participation before any trial-related activities.
- Patients aged 18 years or older.
- Patients initiating injectable anticancer treatment (chemotherapy, immunotherapy, targeted therapies etc.).
- Patients with the capacity, personally (e.g., language and capacity to use the application), and in terms of infrastructure (internet access, possessing a smart phone etc.) to perform Cureety telemonitoring.
- Patient affiliated to an appropriate social security system
Non-inclusion criteria
- Exclusive oral cancer treatment
- Patient with dysphonia or difficulty communicating orally
- Patient benefiting from injectable cancer treatment as part of a clinical trial
- Inability to undergo trial monitoring for geographical, social or psychological reasons
- Any associated medical or psychological condition that could compromise the patient's ability to participate in the study
- Patient deprived of freedom or under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cureety telemonitoring
The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression.
The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
|
The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression.
The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
|
Active Comparator: OPTIMA or equivalent programs
The programs consist of three stages:
|
The programs consist of three stages:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of adding Cureety telemonitoring to usual care
Time Frame: 2 months
|
Measured by number of outgoing calls to patients performing injectable anticancer treatments
|
2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Audrey FAVEYRIAL, MD, Centre François Baclesse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2023-A02762-43
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Patients Initiating Injectable Anticancer
-
Indonesia UniversityCompletedAdult Patients Undergoing ERCPIndonesia
-
University of ArizonaUnknown
-
Govind Ballabh Pant HospitalCompletedAdult Cardiac Surgical PatientsIndia
-
Hospital Ernesto DornellesFederal University of Rio Grande do Sul; Hospital Moinhos de VentoUnknownDifficult-to-wean Adult PatientsBrazil
-
Poitiers University HospitalCompletedMajor Surgery in Adult PatientsFrance
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive TherapyChina
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; University... and other collaboratorsRecruitingCancer Patients | Supportive Care | Young AdultUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; Centre Hospitalier Universitaire de Saint Etienne; University... and other collaboratorsCompletedAdult Patients Ventilated More Than 48 hFrance
-
Indonesia UniversityCompletedAdult Patients Undergoing Phacoemulsification With Topical AnesthesiaIndonesia
Clinical Trials on Cureety telemonitoring
-
CureetyCompleted
-
Centre Hospitalier de BlignyCureety; Exystat; Pharmaspecific; ProPensRecruiting
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandRecruiting
-
ResMedCompleted
-
Chang Hee, LeePurdue University; LG Electronics Inc.CompletedHypertensionKorea, Republic of
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Societat Catalana de Pneumologia...RecruitingNon Invasive VentilationSpain
-
Istituto Auxologico ItalianoRecruiting
-
humanITcareUniversity of Barcelona; Hospital Universitario de Torrevieja; European Innovation...RecruitingHeart FailureSpain, Romania
-
Research and Practical Clinical Center for Diagnostics...Sechenov UniversityEnrolling by invitationInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisRussian Federation
-
Hospital Universitari de BellvitgeInstitut d'Investigació Biomèdica de BellvitgeCompleted